Literature DB >> 22271433

Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.

Filippo Pietrantonio1, Pamela Biondani, Alessandro Pellegrinelli, Alfonso Marchianò, Katia Fiorella Dotti, Roberto Buzzoni, Maria Di Bartolomeo.   

Abstract

A 48-year-old man was referred to our hospital with the diagnosis of colon cancer with multiple hepatic metastases. After right hemicolectomy, the rapid progression of liver disease was treated with metronomic capecitabine and bevacizumab according to a study protocol. A gradual regression of metastatic lesions was observed during a 9-month treatment period. After conversion of liver disease to resectability, the histological examination disclosed the complete necrosis of all lesions, with the exception of small neoplastic foci inside a single nodule. The comparison of this type of histological findings with the classic sclero-hyaline pathological response, as well as its importance as indicator of response to antiangiogenic treatment, is discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271433     DOI: 10.1007/s12032-011-0132-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

1.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

Authors:  D Hanahan; G Bergers; E Bergsland
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

3.  Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

Authors:  Stéphane Benoist; Antoine Brouquet; Christophe Penna; Catherine Julié; Mostafa El Hajjam; Sophie Chagnon; Emmanuel Mitry; Philippe Rougier; Bernard Nordlinger
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

4.  Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy.

Authors:  Lorena Losi; Gabriele Luppi; Margherita Gavioli; Francesco Iachetta; Federica Bertolini; Roberto D'Amico; Gordana Jovic; Filippo Bertoni; Anna Maria Falchi; Pier Franco Conte
Journal:  Int J Colorectal Dis       Date:  2005-11-30       Impact factor: 2.571

5.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

Authors:  Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

Review 6.  Biomarkers of response and resistance to antiangiogenic therapy.

Authors:  Rakesh K Jain; Dan G Duda; Christopher G Willett; Dushyant V Sahani; Andrew X Zhu; Jay S Loeffler; Tracy T Batchelor; A Gregory Sorensen
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

7.  Urgent need for a new staging system in advanced colorectal cancer.

Authors:  Graeme J Poston; Joan Figueras; Felice Giuliante; Gennaro Nuzzo; Alberto F Sobrero; Jean-Francois Gigot; Bernard Nordlinger; Rene Adam; Thomas Gruenberger; Michael A Choti; Anton J Bilchik; Eric J D Van Cutsem; Jy-Ming Chiang; Michael I D'Angelica
Journal:  J Clin Oncol       Date:  2008-08-18       Impact factor: 44.544

Review 8.  Modes of resistance to anti-angiogenic therapy.

Authors:  Gabriele Bergers; Douglas Hanahan
Journal:  Nat Rev Cancer       Date:  2008-08       Impact factor: 60.716

9.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

10.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

View more
  1 in total

1.  GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.

Authors:  Filippo Pietrantonio; Rosa Berenato; Claudia Maggi; Marta Caporale; Massimo Milione; Federica Perrone; Elena Tamborini; Dario Baratti; Shigeki Kusamura; Luigi Mariani; Monica Niger; Alessia Mennitto; Annunziata Gloghini; Ilaria Bossi; Giulio Settanni; Adele Busico; Pietro Francesco Bagnoli; Maria Di Bartolomeo; Marcello Deraco; Filippo de Braud
Journal:  J Transl Med       Date:  2016-05-06       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.